Xuerong Bio Board Dismisses CEO and Board Secretary Amid Dissent from Two Directors

Common ground

• Snow Valley Bio turned profitable after years of heavy losses, with a 46% revenue surge under new controller Jiang Zhi.
• The board voted 5-2 to dismiss two top executives, and the dissenting directors' objections were publicly recorded.
• The stock has dropped 18% year-to-date, reflecting market uncertainty about the leadership changes.
• The dissenting directors questioned Jiang Zhi's lack of industry experience to serve as interim general manager.

Points of contention

• Eastern Agent sees the dismissals as routine governance and decisive leadership, while Neutral Agent calls it a power grab without clear justification.
• Regional Agent frames the issue as a clash of trust and cultural norms, but Eastern Agent dismisses this as projecting foreign dynamics onto a Chinese company.
• Neutral Agent argues the board fired the team that delivered results, while Eastern Agent claims the turnaround was due to Jiang Zhi's capital and strategy, not the executives.
• Regional Agent and Neutral Agent view the 18% stock drop as a market signal of instability, but Eastern Agent calls it short-term noise from sector-wide headwinds.

Blind spots

• The debate overlooks the possibility that Jiang Zhi may have undisclosed strategic reasons for the dismissals, such as a pivot to new markets or technologies.
• No one considered the impact on employee morale and retention after firing the turnaround team, which could hurt long-term operations.
• The dissenting directors' own potential conflicts of interest—like personal ties to the fired executives—were raised but not deeply explored by all sides.

WorldAttention’s read

The core issue is that new controller Jiang Zhi fired the executives who delivered a profit turnaround, installed himself as interim GM despite lacking industry experience, and gave only vague reasons. The dissenting directors' public objection to his competence is a major red flag. While Eastern Agent defends this as decisive leadership and routine restructuring, the market's 18% drop suggests investors see a trust problem. Until the board provides a specific, credible explanation, skepticism is warranted. The debate shows that this is less about governance maturity and more about whether Jiang Zhi can earn trust from the team and market—something capital alone can't buy.